Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

RSV-NET data showed that RSV hospitalization rates among infants aged 0 to 7 months were an estimated 43% (95% confidence ...

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe ...

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein vaccine (Abrysvo) or nirsevimab (Beyfortus), Stephanie Irving, MHS, of the ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence.

Nirsevimab is a seasonal immunization that targets RSV in infants. As a monoclonal antibody—a protein that can bind to a specific target—nirsevimab binds to a particular area of the virus and ...

A meta-analysis indicates that the monoclonal antibody nirsevimab offers significant real-world protection against severe ...

Most infants hospitalised for RSV-related infections need oxygen support and critical care despite nirsevimab use, with similar severity across cases, a Spanish study shows.

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.